Circulating oxidized low-density lipoprotein is increased in hypertension.

Oxidized low-density lipoprotein (OxLDL) and autoantibodies to OxLDL (aOxLDL) are implicated in the development of atherosclerosis. The objective of this study was to determine the importance of these factors in hypertension, a major risk factor for atherosclerosis. Samples were obtained from 111 men with established hypertension (diastolic pressure >95 mmHg) from the Swedish component of an ongoing hypertension study (European Lacidipine study on Atherosclerosis, ELSA) and from 75 normotensive control men, who were from a Swedish population-screening programme (diastolic pressure <80 mmHg). The presence of carotid atherosclerosis and the intima-media thicknesses were determined by ultrasonography. A monoclonal antibody to OxLDL, EO6, was used to determine oxidation epitopes in LDL. aOxLDL of IgG and IgM subclass were tested by ELISA against OxLDL. Hypertensive men had increased OxLDL levels compared with normotensives ( P =0.002), whereas autoantibodies tested were largely similar between groups. There was no association between the antibodies tested, or OxLDL and carotid atherosclerosis. Age was not associated with OxLDL or aOxLDL measurements. Taken together, our findings indicate that OxLDL is elevated in hypertensive men, which may predispose to atherosclerosis in hypertension. In contrast, aOxLDL levels were unchanged and the role of aOxLDL may depend on disease stage and/or type.

[1]  G. Mancia,et al.  Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial , 2002, Circulation.

[2]  P. Libby,et al.  Lipid Lowering Reduces Oxidative Stress and Endothelial Cell Activation in Rabbit Atheroma , 2002, Circulation.

[3]  U. de Faire,et al.  Circulating heat shock protein and heat shock protein antibody levels in established hypertension , 2002, Journal of hypertension.

[4]  Peter Libby,et al.  Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis , 2002, Circulation research.

[5]  D. Rader,et al.  Absence of 12/15-Lipoxygenase Expression Decreases Lipid Peroxidation and Atherogenesis in Apolipoprotein E—Deficient Mice , 2001, Circulation.

[6]  G. Chisolm,et al.  Oxidized LDL-induced injury and apoptosis in atherosclerosis. Potential roles for oxysterols. , 2001, Trends in cardiovascular medicine.

[7]  Christopher K. Glass,et al.  Atherosclerosis The Road Ahead , 2001, Cell.

[8]  OlovWiklund,et al.  Antibodies to Oxidized LDL in Relation to Carotid Atherosclerosis, Cell Adhesion Molecules, and Phospholipase A2 , 2001 .

[9]  J. Witztum,et al.  Circulating Autoantibodies to Oxidized LDL Correlate With Arterial Accumulation and Depletion of Oxidized LDL in LDL Receptor–Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[10]  G. Silverman,et al.  Immunological responses to oxidized LDL. , 2000, Free radical biology & medicine.

[11]  R. Touyz,et al.  Oxidative stress and vascular damage in hypertension , 2000, Current hypertension reports.

[12]  U. de Faire,et al.  Antibodies to platelet‐activating factor are associated with borderline hypertension, early atherosclerosis and the metabolic syndrome , 1999, Journal of internal medicine.

[13]  J. Berliner,et al.  Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis : in vitro and In vivo inhibition by WEB 2086. , 1999, Circulation research.

[14]  U. Andersson,et al.  Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. , 1999, Atherosclerosis.

[15]  E. Dennis,et al.  Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. , 1999, The Journal of clinical investigation.

[16]  U. de Faire,et al.  Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. , 1999, Hypertension.

[17]  E. Miller,et al.  Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[18]  U. de Faire,et al.  Antibodies to endothelial cells in borderline hypertension. , 1998, Circulation.

[19]  Giuseppe Mancia,et al.  Risk factors associated with alterations in carotid intima—media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis , 1998, Journal of hypertension.

[20]  Wei Sha,et al.  Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence in Vivo * , 1997, The Journal of Biological Chemistry.

[21]  U. de Faire,et al.  Association of serum antibodies to heat-shock protein 65 with borderline hypertension. , 1997, Hypertension.

[22]  J. Witztum,et al.  Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. , 1996, The Journal of clinical investigation.

[23]  M. Bond,et al.  Ultrasound protocol and quality control procedures in the European Lacidipine Study on Atherosclerosis (ELSA). , 1996, Blood pressure. Supplement.

[24]  M. Fu.  Do immune system changes have a role in hypertension? , 1995, Journal of hypertension.

[25]  U. de Faire,et al.  Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[26]  E. Miller,et al.  Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Bond,et al.  Potential Modification of Plaque Behavior Through the European Lacidipine Study on Atherosclerosis , 1995, Journal of cardiovascular pharmacology.

[28]  G. Bellomo,et al.  Presence of autoantibodies against oxidatively modified low‐density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low‐density lipoprotein oxidation , 1995, Journal of hypertension.

[29]  LeenaTenkanen,et al.  Anti-Cardiolipin Antibodies and Risk of Myocardial Infarction in a Prospective Cohort of Middle-Aged Men , 1995 .

[30]  U. de Faire,et al.  Carotid intima-media thickness and plaque in borderline hypertension. , 1995, Stroke.

[31]  J. Salonen,et al.  Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.

[32]  R. Giscombe,et al.  Induction of T-cell activation by oxidized low density lipoprotein. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[33]  D. Dzielak.  The immune system and hypertension. , 1992, Hypertension.

[34]  M. Gidlund,et al.  Biologically modified LDL increases the adhesive properties of endothelial cells. , 1991, Atherosclerosis.

[35]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[36]  M. Territo,et al.  Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. , 1990, The Journal of clinical investigation.

[37]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[38]  A. Hamsten,et al.  Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Hamsten,et al.  Low density lipoprotein-induced growth of U937 cells: a novel method to determine the receptor binding of low density lipoprotein. , 1990, Journal of lipid research.

[40]  S. Young,et al.  Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. , 1986, Clinical chemistry.

[41]  G. Hughes.  Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. , 1983, British medical journal.

[42]  T. Henriksen,et al.  Injury to human endothelial cells in culture induced by low density lipoproteins. , 1979, Scandinavian journal of clinical and laboratory investigation.

[43]  B. Kristensen.  Increased serum levels of immunoglobulins in untreated and treated essential hypertension. I. Relation to blood pressure. , 2009, Acta medica Scandinavica.